Earnings Call Insights: Madrigal Pharmaceuticals (MDGL) Q2 2026 Management View – “Second quarter 2026 net sales were $364 million, representing year-over-year growth of 71%” and “we steadily add patients quarter-over-quarter” with “more than 49,000 active patients on Rezdiffra”…
quarter end, while “momentum remains strong” after the company “surpassed the 50,000 patient Seeking Alpha’s Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed
This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank